Clarity Pharmaceuticals (ASX:CU6) OCF Yield %: -10.67 (As of Jun. 28, 2026)


ASX:CU6 Clarity Pharmaceuticals Ltd ASX:CU6
39 GF Score
Price A$1.82
! 2 Warning Signs
View Full Analysis

What is Clarity Pharmaceuticals OCF Yield %?

Clarity Pharmaceuticals ASX:CU6 -11.03% 39 OCF Yield % is -10.67 as of Jun. 28, 2026. GuruFocus rates ASX:CU6 with a GF Score™ of 39/100. The stock has 2 warning signs investors should review. Among 1,417 Biotechnology companies, Clarity Pharmaceuticals ranks worse than 54.62% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, Clarity Pharmaceuticals's Trailing 12-Month Cash Flow from Operations is A$-72.26 Mil, and Market Cap is A$676.94 Mil. Therefore, Clarity Pharmaceuticals's OCF Yield % for today is -10.67%.

The historical rank and industry rank for Clarity Pharmaceuticals's OCF Yield % or its related term are showing as below:

ASX:CU6' s OCF Yield % Range Over the Past 10 Years
Min: -10.67   Med: 0   Max: -10.67
Current: -10.67


During the past 4 years, the highest OCF Yield % of Clarity Pharmaceuticals was -10.67%. The lowest was -10.67%. And the median was %.

ASX:CU6's OCF Yield % is ranked worse than
54.62% of 1417 companies
in the Biotechnology industry
Industry Median: -8.4 vs ASX:CU6: -10.67

Clarity Pharmaceuticals's OCF Margin % for the quarter that ended in Dec. 2025 was %.


Clarity Pharmaceuticals OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Clarity Pharmaceuticals OCF Yield % Related Terms


Clarity Pharmaceuticals OCF Yield % Historical Data

* Premium members only.

The historical data trend for Clarity Pharmaceuticals's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clarity Pharmaceuticals OCF Yield % Chart

Clarity Pharmaceuticals Annual Data
Trend Jun22 Jun23 Jun24 Jun25
OCF Yield %
-10.12 -29.74 -2.56 -6.81

Clarity Pharmaceuticals Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only -21.04 -1.96 -4.53 -6.09 -7.60

ASX:CU6 vs VRTX, REGN, ALNY: OCF Yield % Comparison

For the Biotechnology subindustry, Clarity Pharmaceuticals's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clarity Pharmaceuticals OCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clarity Pharmaceuticals's OCF Yield % distribution charts can be found below:

* The bar in red indicates where Clarity Pharmaceuticals's OCF Yield % falls into.


ASX:CU6
39GF Score
Clarity Pharmaceuticals Ltd ASX:CU6
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clarity Pharmaceuticals OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

Clarity Pharmaceuticals's OCF Yield % for the fiscal year that ended in Jun. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-54.769 / 803.68
=-6.81%

Clarity Pharmaceuticals's annualized OCF Yield % for the quarter that ended in Dec. 2025 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-47.794 * 2 / 1257.4614
=-7.60%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -10.67 mean?
Clarity Pharmaceuticals (ASX:CU6) has a OCF Yield % of -10.67 as of Jun. 28, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Clarity Pharmaceuticals and its competitors. According to the industry distribution chart, Clarity Pharmaceuticals ranks #774 out of 1417 companies in the Biotechnology industry, placing it in the top 54.6%.
Is Clarity Pharmaceuticals' OCF Yield % too high?
Clarity Pharmaceuticals' current OCF Yield % is -10.67. Based on the distribution chart, Clarity Pharmaceuticals ranks #774 out of 1417 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Clarity Pharmaceuticals has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Clarity Pharmaceuticals' OCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clarity Pharmaceuticals ranks #774 out of 1417 companies for OCF Yield %. This places Clarity Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Clarity Pharmaceuticals and its competitors. Clarity Pharmaceuticals's current OCF Yield % is -10.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clarity Pharmaceuticals stock overvalued right now?
Clarity Pharmaceuticals (ASX:CU6) has a current OCF Yield % of -10.67. The current OCF Yield % is -10.67. Clarity Pharmaceuticals' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Clarity Pharmaceuticals (ASX:CU6), the current OCF Yield % is -10.67 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Clarity Pharmaceuticals Business Description

Other Exchanges CLRPF:USA1F4:Germany
Address 2-4 Cornwallis Street, Suite 212a, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, using its SAR Technology platform. Clarity's Targeted Copper Theranostic (TCT) platform of products utilize pairing of copper isotopes, specifically copper-64 (Cu-64 or 64Cu) for imaging and copper-67 Cu-67 or 67Cu) for therapy, which delivers accuracy and precision in the treatment of a range of cancers. The company's clinical development pipeline includes SAR-bisPSMA, SAR-Bombesin, and Sartate, in their different stages of development for the diagnosis and/or treatment of various cancers. Clarity operates in a single segment, which is the development of radiopharmaceuticals. Geographically, it operates in Australia and the United States.
39GF Score

Get the complete analysis for ASX:CU6

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.82
Price